6.
Pinto A, Lippard S
. Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA. Biochim Biophys Acta. 1985; 780(3):167-80.
DOI: 10.1016/0304-419x(85)90001-0.
View
7.
den Hartog J, Altona C, Chottard J, Girault J, Lallemand J, de Leeuw F
. Conformational analysis of the adduct cis-[Pt(NH3)2 d(GpG)]+ in aqueous solution. A high field (500-300 MHz) nuclear magnetic resonance investigation. Nucleic Acids Res. 1982; 10(15):4715-30.
PMC: 321124.
DOI: 10.1093/nar/10.15.4715.
View
8.
Todd R, Lippard S
. Inhibition of transcription by platinum antitumor compounds. Metallomics. 2010; 1(4):280-91.
PMC: 2752884.
DOI: 10.1039/b907567d.
View
9.
Marzilli L, Saad J, Kuklenyik Z, Keating K, Xu Y
. Relationship of solution and protein-bound structures of DNA duplexes with the major intrastrand cross-link lesions formed on cisplatin binding to DNA. J Am Chem Soc. 2001; 123(12):2764-70.
DOI: 10.1021/ja0007915.
View
10.
Brabec V, Malina J, Margiotta N, Natile G, Kasparkova J
. Thermodynamic and mechanistic insights into translesion DNA synthesis catalyzed by Y-family DNA polymerase across a bulky double-base lesion of an antitumor platinum drug. Chemistry. 2012; 18(48):15439-48.
DOI: 10.1002/chem.201202117.
View
11.
Petruzzella E, Margiotta N, Ravera M, Natile G
. NMR investigation of the spontaneous thermal- and/or photoinduced reduction of trans dihydroxido Pt(IV) derivatives. Inorg Chem. 2013; 52(5):2393-403.
DOI: 10.1021/ic302100x.
View
12.
Lebwohl D, Canetta R
. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer. 1999; 34(10):1522-34.
DOI: 10.1016/s0959-8049(98)00224-x.
View
13.
Margiotta N, Marzano C, Gandin V, Osella D, Ravera M, Gabano E
. Revisiting [PtCl₂(cis-1,4-DACH)]: an underestimated antitumor drug with potential application to the treatment of oxaliplatin-refractory colorectal cancer. J Med Chem. 2012; 55(16):7182-92.
DOI: 10.1021/jm3006838.
View
14.
Wu Y, Bhattacharyya D, King C, Baskerville-Abraham I, Huh S, Boysen G
. Solution structures of a DNA dodecamer duplex with and without a cisplatin 1,2-d(GG) intrastrand cross-link: comparison with the same DNA duplex containing an oxaliplatin 1,2-d(GG) intrastrand cross-link. Biochemistry. 2007; 46(22):6477-87.
PMC: 2129171.
DOI: 10.1021/bi062291f.
View
15.
Margiotta N, Petruzzella E, Platts J, Mutter S, Deeth R, Ranaldo R
. DNA fragment conformations in adducts with Kiteplatin. Dalton Trans. 2014; 44(8):3544-56.
DOI: 10.1039/c4dt01796j.
View
16.
Mutter S, Margiotta N, Papadia P, Platts J
. Computational evidence for structural consequences of kiteplatin damage on DNA. J Biol Inorg Chem. 2014; 20(1):35-48.
DOI: 10.1007/s00775-014-1207-5.
View
17.
Paquet F, Perez C, Leng M, Lancelot G, Malinge J
. NMR solution structure of a DNA decamer containing an interstrand cross-link of the antitumor drug cis-diamminedichloroplatinum (II). J Biomol Struct Dyn. 1996; 14(1):67-77.
DOI: 10.1080/07391102.1996.10508930.
View
18.
Bhattacharyya D, Ramachandran S, Sharma S, Pathmasiri W, King C, Baskerville-Abraham I
. Flanking bases influence the nature of DNA distortion by platinum 1,2-intrastrand (GG) cross-links. PLoS One. 2011; 6(8):e23582.
PMC: 3154474.
DOI: 10.1371/journal.pone.0023582.
View
19.
Kelland L
. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007; 7(8):573-84.
DOI: 10.1038/nrc2167.
View
20.
Girault J, Chottard G, Lallemand J, Chottard J
. Interaction of cis-[Pt(NH3)2(H2O)2](NO3)2 with ribose deoxyribose diguanosine phosphates. Biochemistry. 1982; 21(6):1352-6.
DOI: 10.1021/bi00535a038.
View